Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs

Lexaria Bioscience Corp. has received five new patents, including two for diabetes treatment utilizing GLP-1 drugs, as part of its ongoing R&D efforts. The new patents include two granted in Japan for hypertension treatment and one in Australia for epilepsy treatment, with terms extending into the 2040s. Additionally, the company has secured two new Australian patents for diabetes treatment, further expanding its intellectual property portfolio. Lexaria anticipates receiving more patent awards in the future.